EpiVario

About:

EpiVario develops novel compounds to treat memory-related psychiatric disorders at the source of the disease.

Twitter/X: epivario

Top Investors: National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism

Description:

EpiVario is a preclinical pharmaceutical company that develops novel compounds for the goal of reducing or preventing the pathogenesis of psychiatric diseases: post-traumatic stress disorder (PTSD) and substance abuse disorders. EpiVario was founded in 2017 and is based in Philadelphia, Pennsylvania.

Total Funding Amount:

$1.28M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Philadelphia, Pennsylvania, United States

Founded Date:

2017-01-01

Founders:

Philipp Mews, Shelley Berger

Number of Employees:

1-10

Last Funding Date:

2024-10-01

IPO Status:

Private

Industries: